Clinical Trials Logo

Dilated Cardiomyopathy (DCM) clinical trials

View clinical trials related to Dilated Cardiomyopathy (DCM).

Filter by:
  • None
  • Page 1

NCT ID: NCT02413450 Enrolling by invitation - Clinical trials for Hypertrophic Cardiomyopathy (HCM)

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

Start date: August 2013
Phase:
Study type: Observational [Patient Registry]

Human induced pluripotent stem cells (hiPSCs) have driven a paradigm shift in the modeling of human disease; the ability to reprogram patient-specific cells holds the promise of an enhanced understanding of disease mechanisms and phenotypic variability, with applications in personalized predictive pharmacology/toxicology, cell therapy and regenerative medicine. This research will collect blood or skin biopsies from patients and healthy controls for the purpose of generating cell and tissue models of Mendelian heritable forms of heart disease focusing on cardiomyopathies, channelopathies and neuromuscular diseases. Cardiomyocytes derived from hiPSCs will provide a ready source of disease specific cells to study pathogenesis and therapeutics.

NCT ID: NCT02293603 Active, not recruiting - Heart Failure Clinical Trials

Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)

DYNAMIC
Start date: November 2014
Phase: Phase 1
Study type: Interventional

To determine the safety profile of CAP-1002 administered by multi-vessel intracoronary infusion in subjects with DCM. The study will further explore safety and exploratory efficacy endpoints of CAP-1002.

NCT ID: NCT00523653 Recruiting - Clinical trials for Dilated Cardiomyopathy (DCM)

The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study

Start date: January 2008
Phase: N/A
Study type: Observational

Dilated cardiomyopathy (DCM) affects about 200,000 Canadians. Eighty percent of these cases are of unclear cause, often occuring in families. We believe that mutations in specific already-identified genes contribute to DCM in Quebec and that certain mutations may account for a significant proportion of cases due to the well-documented "founder effect". Two hundred patients with DCM followed in our Heart Function Clinic will be approached for one blood sample at their routine clinic visit to test this hypothesis. The samples will be tested in the Laboratory of Cardiovascular Genetics at the Royal Victoria Hospital.